MX2018010894A - Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma. - Google Patents

Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma.

Info

Publication number
MX2018010894A
MX2018010894A MX2018010894A MX2018010894A MX2018010894A MX 2018010894 A MX2018010894 A MX 2018010894A MX 2018010894 A MX2018010894 A MX 2018010894A MX 2018010894 A MX2018010894 A MX 2018010894A MX 2018010894 A MX2018010894 A MX 2018010894A
Authority
MX
Mexico
Prior art keywords
phosphatidylinositol
kinase gamma
novel inhibitors
compounds
pi3k
Prior art date
Application number
MX2018010894A
Other languages
English (en)
Inventor
Mogemark Mickael
Pemberton Nils
Petersen Jens
Perry Matthew
Karabelas Konstantinos
Zlatoidsky Pavol
Cox Rhona
Tyrchan Christian
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2018010894A publication Critical patent/MX2018010894A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen determinados nuevos compuestos (incluyendo sales farmacéuticamente aceptables de los mismos), (ver Fórmula) que inhiben la actividad de fosfatidilinositol 3-quinasa gamma (PI3K?), a su utilidad en tratar y/o prevenir afecciones clínicas, incluyendo enfermedades respiratorias tales como asma y enfermedad pulmonar obstructiva crónica (COPD), a su uso en terapia, a composiciones farmacéuticas que los contienen y a procedimientos para preparar estos compuestos.
MX2018010894A 2016-03-10 2017-03-09 Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma. MX2018010894A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662306328P 2016-03-10 2016-03-10
PCT/EP2017/055552 WO2017153527A1 (en) 2016-03-10 2017-03-09 Novel inhibitors of phosphatidylinositol 3-kinase gamma

Publications (1)

Publication Number Publication Date
MX2018010894A true MX2018010894A (es) 2018-11-09

Family

ID=58264542

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010894A MX2018010894A (es) 2016-03-10 2017-03-09 Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma.

Country Status (13)

Country Link
US (2) US10858355B2 (es)
EP (1) EP3426652B1 (es)
JP (1) JP6893520B2 (es)
KR (1) KR20180117693A (es)
CN (1) CN108779110B (es)
AR (1) AR107840A1 (es)
AU (1) AU2017229445B2 (es)
BR (1) BR112018068075A2 (es)
CA (1) CA3015893C (es)
EA (1) EA036388B1 (es)
MX (1) MX2018010894A (es)
TW (1) TWI746525B (es)
WO (1) WO2017153527A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11396502B2 (en) 2018-11-13 2022-07-26 Incyte Corporation Substituted heterocyclic derivatives as PI3K inhibitors
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102198A1 (en) * 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
US20230227446A9 (en) * 2019-04-10 2023-07-20 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphatidylinositol 3-kinase inhibitors
CN114258393A (zh) * 2020-07-21 2022-03-29 中国医药研究开发中心有限公司 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途
WO2024046454A1 (zh) * 2022-09-01 2024-03-07 上海海雁医药科技有限公司 杂芳基取代的吡啶并吡咯酮衍生物、其药物组合物及应用
CN117683036A (zh) * 2022-09-09 2024-03-12 上海璎黎药业有限公司 一种含氮杂环化合物、其药物组合物及应用
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
WO2006089106A2 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
ES2389062T3 (es) * 2006-01-18 2012-10-22 Amgen, Inc Compuestos de tiazol como inhibidores de proteína cinasa B (PKB)
WO2007129044A1 (en) * 2006-05-03 2007-11-15 Astrazeneca Ab Thiazole derivatives and their use as anti-tumour agents
EP1894931A1 (en) * 2006-08-30 2008-03-05 Cellzome Ag Triazole derivatives as kinase inhibitors
US20110230472A1 (en) * 2008-08-29 2011-09-22 Shionogi & Co., Ltd. Ring-fused azole derivative having pi3k-inhibiting activity
MX2011008645A (es) * 2009-02-17 2011-09-30 Vertex Pharma Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
SG10201502073PA (en) * 2009-12-22 2015-05-28 Vertex Pharma Isoindolinone inhibitors of phosphatidylinositol 3-kinase
CN104379573A (zh) * 2012-04-20 2015-02-25 艾伯维公司 异吲哚酮衍生物
ES2687593T3 (es) * 2013-09-25 2018-10-26 Vertex Pharmaceuticals Inc. Un inhibidor selectivo de fosfatidilinositol 3-quinasa-gamma
CN106458980A (zh) 2014-04-24 2017-02-22 诺华股份有限公司 作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物
MX2016013812A (es) 2014-04-24 2017-03-09 Novartis Ag Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa.
CN106458966B (zh) 2014-04-24 2019-05-07 诺华股份有限公司 作为磷脂酰肌醇3-激酶抑制剂的吡嗪衍生物

Also Published As

Publication number Publication date
TW201808945A (zh) 2018-03-16
AU2017229445B2 (en) 2019-07-11
WO2017153527A1 (en) 2017-09-14
JP6893520B2 (ja) 2021-06-23
CA3015893C (en) 2021-11-09
BR112018068075A2 (pt) 2019-01-08
AR107840A1 (es) 2018-06-13
US10858355B2 (en) 2020-12-08
EP3426652A1 (en) 2019-01-16
KR20180117693A (ko) 2018-10-29
EA036388B1 (ru) 2020-11-03
CA3015893A1 (en) 2017-09-14
US20210047312A1 (en) 2021-02-18
JP2019507788A (ja) 2019-03-22
US20200299289A1 (en) 2020-09-24
AU2017229445A1 (en) 2018-10-25
EP3426652B1 (en) 2021-12-01
TWI746525B (zh) 2021-11-21
CN108779110B (zh) 2021-10-29
CN108779110A (zh) 2018-11-09
EA201891931A1 (ru) 2019-04-30

Similar Documents

Publication Publication Date Title
MX2018010894A (es) Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma.
PH12016501439A1 (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
PH12015501965B1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
NZ711424A (en) Pyridine derivatives as soft rock inhibitors
PH12015502563A1 (en) Bipyrazole derivatives as jak inhibitors
SG10201805033XA (en) Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
PH12019500615A1 (en) 5-[2-(PYRIDIN-2-YLAMINO)-1,3-THIAZOL-5-YL]-2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND THEIR USE AS DUAL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE DELTA and GAMMA
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
PH12017502087A1 (en) Tiotropium inhalation solution for nebulization
GB201302704D0 (en) Therapeutic compounds
MX2019007213A (es) Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina.
MX2019007360A (es) Derivado de triazol azabiciclo-sustituido, preparacion, metodo del mismo, y aplicacion de la misma en medicina.